Skip to content
stocks-llm

CRINETICS PHARMACEUTICALS INC (CRNX)

Health Care · Biotechnology · NASDAQ

Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors.

View SEC filings Filings archive → Large price moves → Website Find companies like CRNX → Ask about CRNX →

What CRINETICS PHARMACEUTICALS INC does

Crinetics Pharmaceuticals is a clinical-stage precision medicine company focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's platform is built around the discovery of small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its pipeline includes therapeutics for conditions such as acromegaly, Cushing’s disease, and congenital adrenal hyperplasia.

Themes: rare disease therapies, endocrine system disorders, precision medicine, drug discovery and development

Fundamentals

  • Price$84.95 last close before the listing ended, 2026-09-02
  • Market cap$9.0B as of 2026-07-22 (share count; price 2026-09-02)
  • 1-year return+155.1% 2025-09-02 close $33.30 → 2026-09-02 close $84.95
  • P/En/a negative earnings
  • Net margin-6046.2% FY2025, SEC XBRL
  • ROE-46.9% FY2025, SEC XBRL
  • Debt / equity0.00 as of 2026-09-03
  • Revenue growth (YoY)+640.7% FY2025 vs FY2024, SEC XBRL
  • Beta1.07 as of 2026-09-03
  • Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)

This listing has ended. The figures below are the last on record, from 2026-09-02, not a current quote.

Ask why CRNX looks like this →

How CRNX compares in its sector

  • net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
  • operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
  • return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
  • free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025

Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.

Ask how CRNX stacks up against peers →

Analyst consensus

  • Consensus ratingHold (2.78 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
  • Mean price target$85.00 range $85.00 – $85.00

Analyst estimates, as of 2026-09-10. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for CRNX

  • Consensus EPS estimate-$1.13 next reporting period, as of 2026-09-10

Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how CRNX's estimates have moved →

Key risks (from latest filing)

["The company has a history of losses, is currently unprofitable, and expects to continue to incur significant expenses as it advances its clinical pipeline.","Dependence on the success of its lead product candidates for the treatment of rare endocrine diseases.","Risks associated with the regulatory approval process and potential difficulties in commercializing new pharmaceutical products."]

See CRNX's biggest risks from its latest 10-Q →

What changed in the latest 10-Q

AI-assisted comparison of CRNX's 10-Q filed 2026-08-03 against the prior one filed 2026-05-07.

Management's Discussion & Analysis (MD&A)

  • Added:
    • Newer filing (2026-08-03) adds merger-related forward-looking statements, including expectations regarding the timing and completion of the Merger with Vertex and the Transactions.
    • Newer filing (2026-08-03) adds a 'Recent Developments - Merger with Vertex Pharmaceuticals Incorporated' subsection stating that on July 6, 2026, the Company entered into a Merger Agreement with Vertex and Merger Sub, and the Merger is expected to close in the third quarter of 2026.
    • Newer filing (2026-08-03) adds that received 245 Enrollment Forms during the second quarter of 2026.
    • Newer filing (2026-08-03) adds that 385 unique HCPs had prescribed PALSONIFY within the first three quarters of launch.
    • Newer filing (2026-08-03) adds that over 70% of patients treated with PALSONIFY at the end of the second quarter of 2026 were on reimbursed therapy.
  • Removed:
    • Older filing (2026-05-07) includes a PALSONIFY bullet stating that receivables were 232 Enrollment Forms during the first quarter of 2026; this bullet is not in the newer filing.
    • Older filing (2026-05-07) includes a PALSONIFY bullet stating that 263 unique HCPs had prescribed PALSONIFY within the first two quarters of launch, with approximately 70% of patients on reimbursed therapy at the end of the first quarter of 2026; this bullet is not in the newer filing.
    • Older filing (2026-05-07) includes Paltusotine bullets covering CHMP positive opinion, EC approval of PALSONIFY, MAA submission to Brazil's ANVISA, and SKK NDA submission in Japan; these bullets are not reflected in the newer filing text provided.
    • Older filing (2026-05-07) includes Atumelnant bullets covering TouCAHn study data, BALANCE-CAH study dosing, and EQUILIBRIUM study design; these bullets are not reflected in the newer filing text provided.
    • Older filing (2026-05-07) includes a Paltusotine bullet stating the EC approved PALSONIFY for the medical treatment of adults with acromegaly; this bullet is not in the newer filing text provided.
    • Older filing (2026-05-07) includes a bullet stating that in March 2026 the Company submitted a MAA to Brazil's ANVISA for PALSONIFY for the treatment of acromegaly in adults; this bullet is not in the newer filing text provided.
    • Older filing (2026-05-07) includes a bullet stating that in April 2026 SKK submitted an NDA in Japan for paltusotine for the treatment of acromegaly; this bullet is not in the newer filing text provided.
  • Reworded:
    • Heading changed from 'Forward Looking Statements' in the older filing (2026-05-07) to 'Forward-Looking Statements' in the newer filing (2026-08-03).
    • Newer filing (2026-08-03) describes the risk factors reference as 'Part II, Item 1A, "Risk Factors," in this Report and Part I, Item 1A, "Risk Factors," in our FY 2025 Form 10-K' whereas the older filing (2026-05-07) refers only to 'the "Risk Factors" section contained in our FY 2025 10-K'.
    • Newer filing (2026-08-03) adds 'the commercial potential of PALSONIFY and the anticipated potential of atumelnant and our other pipeline assets' to the list of forward-looking statement topics; this phrase is not in the older filing (2026-05-07).
    • PALSONIFY key metrics description changed from 'first quarter 2026' in the older filing to 'second quarter 2026' in the newer filing.
  • Notes:
    • The provided newer filing text appears truncated, ending mid-sentence in the Paltusotine section, and does not contain the later sections such as Financial operations overview, Critical Accounting Estimates, and Results of Operations that appear in the older filing; therefore only the portions present in both texts could be compared.
    • This comparison is limited to the MD&A text excerpts provided and does not cover the entire MD&A sections of the underlying filings.

Risk Factors

  • Added:
    • Newer filing (filed 2026-08-03) adds an entirely new section titled 'Risks Related to the Merger' containing detailed risk factors about the Merger Agreement, the Merger, and the Transactions, including statements that the Merger is subject to closing conditions including HSR Act waiting period expiration, foreign regulatory clearances, and Company Shareholder Approval, with a possible termination fee of approximately $350.5 million, an expected closing in the third quarter of 2026, and a termination deadline of January 6, 2027 subject to a three-month automatic extension.
    • Newer filing (filed 2026-08-03) adds that neither party can assure the Merger will close, and that a failure to complete the Merger could materially adversely affect the stock price and future business and financial results.
    • Newer filing (filed 2026-08-03) adds discussion that the pendency of the Merger could cause customers, healthcare providers, patients, payors, suppliers, vendors, CROs, CMOs, clinical trial sites, or regulators to delay or defer business decisions.
    • Newer filing (filed 2026-08-03) adds that under the Merger Agreement the company is restricted from entering certain transactions and must conduct business in the ordinary course until the Merger is completed or terminated.
    • Newer filing (filed 2026-08-03) adds concern that current and prospective employees may experience uncertainty about their futures, key employees may depart, and the company may have difficulty hiring new employees during the pendency of the Merger.
    • Newer filing (filed 2026-08-03) adds a statement that because the consideration to be received by shareholders is a fixed cash amount, shareholders will not participate in any potential future upside in the company's business if the Merger is completed.
  • Removed:
    • Older filing (filed 2026-05-07) contained the statement that the company does not believe there have been any material changes to the risk factors set forth in Part I, Item 1A of its FY 2025 Form 10-K; this statement is replaced in the newer filing.
  • Reworded:
    • Older filing (filed 2026-05-07) states there have been no material changes to the risk factors set forth in the FY 2025 Form 10-K, while the newer filing (filed 2026-08-03) states that except as set forth below, there have been no material changes from the risk factors previously disclosed in the FY 2025 Form 10-K, and adds risk factors relating to the Merger.
  • Notes:
    • Newer filing text is truncated mid-sentence at the end of the provided excerpt ('if the Merger is comp'), so changes after that point, if any, are not assessable.
    • The newer filing substitutes 'we' and 'us' and adds references to Vertex, suggesting an M&A context not present in the older filing excerpt.

AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.

Ask what changed in CRNX's latest 10-Q →

Insider activity (SEC Form 4)

No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.

  • Last 180 days · read to 2026-10-040 buys · 3 sells ($366143) — 2 selling insiders

Most recent open-market transaction: 2026-07-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about CRNX's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

U.S. House trading disclosures

U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for CRNX from U.S. House Clerk Periodic Transaction Report filings.

U.S. House trading disclosures →

Institutional ownership (13F)

4 institutional 13F filers reported holding CRNX as of 2026-03-31 (quarter-end position, filed within 45 days).

  • Distinct 13F filers 4
  • Reported shares held 26,987,794
  • Reported value $980,196,686

reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about CRNX's institutional holders → See what each manager we track holds →

Short interest (FINRA)

CRNX had 6,847,147 shares of reported short interest as of the 2026-08-31 FINRA settlement date (delayed, bi-monthly; not real-time).

CRNX had 6.46% of its shares outstanding sold short as of the 2026-08-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.39 days to cover at the same settlement.

  • Reported short interest (shares) 6,847,147
  • Short interest (% of shares outstanding) 6.46%
  • Prior settlement (shares) 6,588,676
  • Reported change 3.92%
  • Days to cover (reported) 2.39

Reported to FINRA as of the 2026-08-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about CRNX's short interest →

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

Compare CRNX vs…

CRINETICS PHARMACEUTICALS INC is found in…

Frequently asked questions

What does CRINETICS PHARMACEUTICALS INC (CRNX) do?

Crinetics Pharmaceuticals is a clinical-stage precision medicine company focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's platform is built around the discovery of small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its pipeline includes therapeutics for conditions such as acromegaly, Cushing’s disease, and congenital adrenal hyperplasia.

What sector is CRINETICS PHARMACEUTICALS INC (CRNX) in?

CRINETICS PHARMACEUTICALS INC (CRNX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.

Who are CRINETICS PHARMACEUTICALS INC's (CRNX) competitors?

Notable peers of CRINETICS PHARMACEUTICALS INC (CRNX) include Ipsen, Novartis, Pfizer, Recordati S.p.A. and Amryt Pharma (acquired by Chiesi). This peer set is informational only — not financial advice.

Has there been recent U.S. House stock trading in CRNX?

Yes — we hold 5 matched STOCK Act disclosures for CRNX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.

Where does stocks-llm's data on CRNX come from?

Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. This listing has ended, so these are the last figures on record rather than current ones — informational only, not financial advice.

Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are the last daily closes recorded before this listing ended.

Last updated 2026-09-02.

Informational only — NOT financial advice. All figures are the last on record before this listing ended, from SEC EDGAR & market data, shown with their as-of date.